Syed Husain is the Chief Executive Officer of BioCentriq, bringing extensive expertise in CDMO development and manufacturing services for both established and emerging modalities. With a career spanning the entire drug development and commercialization lifecycle, Syed has successfully led companies through periods of rapid growth, go-to-market market innovation, and industry disruption. He excels in global business development strategies, enhancing brand visibility, building high-performing teams, optimizing operations, and driving patient-centered, profitable revenue growth.

Prior to joining BioCentriq, Syed was Chief Commercial Officer at Resilience, where he played a key role in building a world-class commercial organization across biologics, vaccines, cell and gene therapies, and nucleic acids. He established a multi-billion-dollar backlog and opportunity pipeline by securing transformative partnerships with leading pharmaceutical and biotech companies. His leadership also fostered a customer-centric culture, supporting sustainable, patient-focused growth. Prior to that, he served in CDMO leadership roles at Emergent BioSolutions, Alcami Corporation and Lonza. He began his career in vaccine manufacturing compliance at Wyeth and across validation, product and process development and manufacturing roles at Pfizer.


Syed holds a Master of Business Administration from Cornell University’s Johnson Graduate School of Management and a Bachelor of Science in Chemical Engineering from the New Jersey Institute of Technology. He serves as an Industrial Advisory Board member for the Otto H York Department of Chemical Engineering at NJIT. He has also served as chair of the Education Committee and on the Advisory Council for the Drug, Chemical & Associated Technologies Association and is involved in the Biotechnology Innovation Organization, Society of Biological Engineers, American Institute of Chemical Engineers and American Chemical Society.

Ck Harinarayan is the VP and Head of Quality & Compliance. She is a seasoned leader with over 25 years of expertise in clinical and commercial Cell Therapy and Biologics, across Quality, Development and Technical Operations. With a solid technical foundation and a strong Quality mindset, she is dedicated to delivering innovative solutions to patients while fostering a culture of inclusion and empowerment. Most recently, as Head of Clinical GMP Quality at Kite Pharma, she spearheaded the implementation of Phase-Appropriate Quality Systems and was responsible for the CMC product quality strategy across Kite’s clinical pipeline programs. Successfully scaled quality at Kite’s El Segundo commercial manufacturing unit and played a pivotal role in the commercialization of Tecartus and Yescarta. Additionally, she has led the design, construction, and operationalization of multiple GMP facilities, including Genentech’s Vacaville Facility, Kite’s RDMC, Clinical Viral Vector and QC laboratories. Throughout her career, Ck has delivered on over 25 successful regulatory inspections and internal auditors in support of products progressing to clinical and commercial milestones. She holds a Bachelor of Science in Chemical Engineering from Birla Institute of Technology and Science and Masters of Science in Chemical Engineering from Colorado State University.

David Smith is the Vice President of Development at BioCentriq, bringing over 15 years of specialized experience in regenerative medicine and engineering. David has demonstrated a solid track record in advancing cell therapy manufacturing through his expertise in areas such as design of experiments, quality-by-design, and cross-functional leadership. In his role, David oversees Manufacturing Science & Technology (MS&T), Process Development, and Analytical Method Development, ensuring BioCentriq’s capabilities align with industry needs and maintain rigorous quality standards. Before joining BioCentriq, David was Vice President of Technical Operations at Ori Biotech, where he spearheaded the technical strategy for Ori’s first cell therapy manufacturing technology, aligning it with industry demands and supporting its adoption through a multi-faceted approach. His previous roles include Director of Research and Development at Minaris Regenerative Medicine, where he contributed to pioneering advancements in cell therapy. David holds a Ph.D. in Regenerative Medicine from Loughborough University and has served on multiple influential committees, including as chair of ARM’s Science and Technology Committee and roles within ISCT, ISO, ASME, and PDA. His extensive involvement with these organizations highlights his commitment to advancing cell therapy standards and innovation across the industry.

Gina Choi brings 14+ years of experience in human resources and managing all general affairs for small to mid-sized companies to her role as Head of HR at BioCentriq. She was previously the Human Resources Business Partner for Line Friends Inc., where she managed all HR activity for two offices and stores in New York and California. Prior to that, she was the Human Resources Manager at CJ TMI Manufacturing America and Grand Supercenter Inc. (H Mart). She has experience managing thousands of employees across multiple states while overseeing the full cycle of each position, developing employee handbooks and compensation structure, and providing HR guidance to management level for coaching, counseling, disciplinary actions, and more. She’s managed commercial insurance, workers’ compensation, health insurance, and 401(k) plans. Gina has her Bachelor of Science in Computer Engineering with a specialization in Systems Analysis from Columbia University of Paraguay. She is also ServSafe Certified and OSHA 30HR Certified. Gina speaks three languages: English, Korean, and Spanish.

Henry Han brings 15+ years of experience to his role as Head of Finance at BioCentriq. He previously served as the Financial and Accounting Team Leader at Ubcare Co. Ltd., which was acquired by GC for $200 million in 2020 and was charged with performing PMI work, such as finance, accounting, IPR, and legal. He headed fund management and cash flow planning and successfully established an e-accounting system to secure stable fund execution and a management process that optimized accounting evidence. Prior to that, Henry was the Finance Team Manager at Green Cross Holdings Corporation, where he was charged with issuing corporate bonds in the public offering bond market, which reached $100 million in 2019. He also managed funds and conducted budget planning, performed governance managing, and managed KPIs. Henry has also previously held the position of Finance Team Assistant Manager at Byuck San Engineering & Construction Co. Ltd. He earned his bachelor’s degree in Business Administration from Chung-Ang University Seoul, Korea.

Joe Sinclair is the VP and Head of Commercial at BioCentriq, he has over 15 years of transformative leadership experience in the life sciences industry. Known for his strategic insight, Joe has focused on driving commercial growth and operational excellence across global CDMO businesses within the biologics and advanced therapeutics sectors. Most recently as Senior Vice President of US Operations and GMP Site Head at uBriGene Biosciences, Joe was responsible for launching the company’s operations with a focus on delivering cell therapy manufacturing solutions. Prior to uBriGene, Joe’s career included leadership and high-impact commercial positions at CDMOs such as Recipharm / Vibalogics, WuXi Advanced Therapies and WuXi AppTec where he was pivotal in driving transitionary business strategy, launching new company facilities and services, and supporting sustained revenue growth and market expansion. He has overseen global sales, business development, commercial operations, and marketing organizations, with a focus on value creation and building strong client and partner relationships, across a deep portfolio of clinical and commercial programs. Joe holds a Bachelor of Science in Business Administration with a concentration in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

Neil Verma is the Sr. Director & Head of Portfolio and Program Management at BioCentriq, bringing over 18 years of experience in program and portfolio management within the biotech industry. With expertise spanning both CDMO and innovator sectors, Neil has a proven track record of driving operational excellence and program success across complex manufacturing environments.

Most recently, as Head of Program Management at Resilience, Neil built and led a high-performing team of project managers, driving customer programs across multiple sites and modalities, including biologics, vaccines, nucleic acids, and cell and gene therapy.  Prior to Resilience, Neil served as Vice President of Manufacturing Strategy and Operations at Athersys, a leading cell therapy innovator, and as Site Program Management Head at Emergent BioSolutions, where he advanced key manufacturing initiatives.   Throughout his career, he played a critical role in integrating newly acquired sites, enabling operational readiness, scaling operations to 24/7 capacity, and embedding a strong service-provider mindset within the organization.  Neil is PMP-certified and holds a Bachelor of Science in Biomedical Engineering from Boston University and an MBA from the University of Maryland Global Campus.

Sun Ra Bullins is the VP and Head of Technical Operations. He has over 20 years in biopharmaceutical operations, he brings a wealth of expertise in GMP production, process development, and continuous improvement. He has successfully led teams to overcome complex challenges—from building cleanrooms to turning around manufacturing sites worldwide. Most recently, while at Excellos, he managed the design and construction of a 10,000 ft² GMP Cell Therapy production facility with multiple ISO 7 cleanrooms. Sun Ra’s leadership at Excellos, Catalent Pharma Solutions, Samsung Biologics and Genentech demonstrates his commitment to building capable, safety-focused teams that value collaboration and quality. He holds a Bachelor of Science in Biology from California State University.